Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773860 | 0.69 | KDM4E (0.34) | TLR7KDM4EGPR3SMN1; SMN2LMNA | |
| SCHEMBL204000 | 0.69 | KDM4E (0.39) | ALDH1A1GABRA1GABRA2TLR7KDM4E | |
| SCHEMBL202424 | 0.67 | KDM4E (0.38) | ALDH1A1TLR7KDM4EGPR3SMN1; SMN2 | |
| SCHEMBL205008 | 0.67 | KDM4E (0.37) | ALDH1A1TLR7KDM4EGPR3SSTR2 | |
| SCHEMBL202597 | 0.67 | KDM4E (0.37) | ALDH1A1TLR7LRRK2KDM4EGPR3 | |
| SCHEMBL1774813 | 0.66 | JAK1 (0.35) | SMN1; SMN2GRM5 | |
| SCHEMBL1774815 | 0.66 | ALDH1A1 (0.34) | ALDH1A1KDM4EGPR3GRM5 | |
| SCHEMBL203276 | 0.66 | CYP3A4 (0.36) | ALDH1A1TLR7KDM4EGPR3SMN1; SMN2 | |
| SCHEMBL203764 | 0.66 | CYP3A4 (0.36) | ALDH1A1TLR7KDM4EGPR3SMN1; SMN2 | |
| SCHEMBL10123167 | 0.66 | KDM4E (0.43) | ALDH1A1KDM4ESMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221551-A1 | SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS | IL2, IFNG, IL4 | ALDH1A1 979/4885GABRA1 1671/4885GABRA2 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.